Marker Therapeutics, Inc. (MRKR)
1.43
+0.02
(+1.42%)
USD |
NASDAQ |
Jun 10, 16:00
1.43
0.00 (0.00%)
After-Hours: 20:00
Marker Therapeutics Enterprise Value : 8.204M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 8.204M |
| June 09, 2026 | 7.870M |
| June 08, 2026 | 8.704M |
| June 05, 2026 | 8.037M |
| June 04, 2026 | 8.871M |
| June 03, 2026 | 8.537M |
| June 02, 2026 | 8.037M |
| June 01, 2026 | 9.704M |
| May 29, 2026 | 10.54M |
| May 28, 2026 | 9.538M |
| May 27, 2026 | 8.537M |
| May 26, 2026 | 8.537M |
| May 22, 2026 | 7.704M |
| May 21, 2026 | 8.204M |
| May 20, 2026 | 7.870M |
| May 19, 2026 | 7.537M |
| May 18, 2026 | 7.537M |
| May 15, 2026 | 8.037M |
| May 14, 2026 | 8.704M |
| May 13, 2026 | 8.204M |
| May 12, 2026 | 8.371M |
| May 11, 2026 | 8.537M |
| May 08, 2026 | 8.704M |
| May 07, 2026 | 8.371M |
| May 06, 2026 | 8.704M |
| Date | Value |
|---|---|
| May 05, 2026 | 9.538M |
| May 04, 2026 | 10.37M |
| May 01, 2026 | 8.704M |
| April 30, 2026 | 8.704M |
| April 29, 2026 | 8.537M |
| April 28, 2026 | 8.037M |
| April 27, 2026 | 8.537M |
| April 24, 2026 | 7.704M |
| April 23, 2026 | 8.537M |
| April 22, 2026 | 10.04M |
| April 21, 2026 | 10.37M |
| April 20, 2026 | 12.21M |
| April 17, 2026 | 12.04M |
| April 16, 2026 | 11.20M |
| April 15, 2026 | 10.70M |
| April 14, 2026 | 10.87M |
| April 13, 2026 | 13.37M |
| April 10, 2026 | 13.54M |
| April 09, 2026 | 13.54M |
| April 08, 2026 | 8.704M |
| April 07, 2026 | 7.537M |
| April 06, 2026 | 7.870M |
| April 02, 2026 | 6.370M |
| April 01, 2026 | 6.203M |
| March 31, 2026 | 6.036M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Krystal Biotech, Inc. | 8.382B |
| Vericel Corp. | 1.858B |
| ADMA Biologics, Inc. | 2.036B |
| Gyre Therapeutics, Inc. | 530.15M |
| Savara, Inc. | 870.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.179M |
| Total Expenses (Quarterly) | 3.179M |
| EPS Diluted (Quarterly) | -0.1646 |
| Earnings Yield | -47.12% |
| Normalized Earnings Yield | -47.11 |